Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1500-1517
Open Access | Times Cited: 91

Showing 26-50 of 91 citing articles:

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 7
Covalent hits and where to find them
Simon C. C. Lucas, J. Henry Blackwell, Sarah H. Hewitt, et al.
SLAS DISCOVERY (2024) Vol. 29, Iss. 3, pp. 100142-100142
Open Access | Times Cited: 6
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 6
D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
Zhe Shi, Jifang Weng, Haotao Niu, et al.
Cancer Science (2023) Vol. 114, Iss. 7, pp. 2951-2960
Open Access | Times Cited: 15
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Lindor Qunaj, Michael May, Alfred I. Neugut, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways
Dan Zhao, Yu Liu, Fengchao Yi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115698-115698
Closed Access | Times Cited: 13
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Jing Zhang, Sun Min Lim, Mi Ra Yu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 9, pp. 1675-1698
Open Access | Times Cited: 5
Structural Insights into Small-Molecule KRAS Inhibitors for Targeting KRAS Mutant Cancers
Divya Pandey, Subhash C. Chauhan, Vivek K. Kashyap, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116771-116771
Closed Access | Times Cited: 5
Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial
Marcelo V. Negrão, Alvaro G. Paula, David Molkentine, et al.
Clinical Cancer Research (2025)
Open Access
Identification of Structurally Novel KRASG12C Inhibitors through Covalent DNA-Encoded Library Screening
David Huang, Francesco Manoni, Zhen Sun, et al.
Journal of Medicinal Chemistry (2025)
Open Access
The Role of Oral Cancer Heterogeneity in Therapies in Various Cellular and Preclinical Models
Priyanka Vijay Sonar, Sachin C. Sarode, Nilesh Kumar Sharma
(2025), pp. 59-77
Closed Access
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
Anirudh Prahallad, Andreas Weiss, Hans Voshol, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4130-4141
Open Access | Times Cited: 12
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Yi Chen, Qiu-pei Liu, Hua Xie, et al.
Acta Pharmacologica Sinica (2023) Vol. 45, Iss. 4, pp. 686-703
Closed Access | Times Cited: 11
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Rameshwar S. Cheke, Prashant S. Kharkar
Drug Development Research (2023) Vol. 85, Iss. 1
Open Access | Times Cited: 11
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Rima Hajjo, Dima A. Sabbah, Sanaa K. Bardaweel, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 1-2, pp. 51-69
Closed Access | Times Cited: 4
Exploring Protein Bioconjugation: A Redox-Based Strategy for Tryptophan Targeting
Qian‐Qian Yang, Shuai‐Jiang Liu, Wei Huang, et al.
Research (2024) Vol. 7
Open Access | Times Cited: 4
Emerging Targets in Non-Small Cell Lung Cancer
Louisa Liu, Joshua Soler, Karen L. Reckamp, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10046-10046
Open Access | Times Cited: 4
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling
Ya‐Fang Wang, Mingyue Yao, Cheng Li, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg
Joshua C. Rosen, Adrian G. Sacher, Ming‐Sound Tsao
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 9
Dynamic conformational equilibria in the active states of KRAS and NRAS
Enrico Rennella, Chrystèle Henry, Callum J. Dickson, et al.
RSC Chemical Biology (2024)
Open Access | Times Cited: 3
Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines
Daiki Yamane, Ryo Tetsukawa, Naoki Zenmyo, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 9130-9146
Closed Access | Times Cited: 8
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Katherina Bernadette Sreter, Maria Joana Catarata, Maximilian von Laffert, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Assessment of KRASG12C inhibitors for colorectal cancer
Gary A. Piazza, Preethi Chandrasekaran, Yulia Maxuitenko, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
KRAS-driven Tumorigenesis and KRAS-driven Therapy in Pancreatic Adenocarcinoma
Minh T. Than, Mark H. O’Hara, Ben Z. Stanger, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 10, pp. 1378-1388
Closed Access | Times Cited: 2

Scroll to top